683 related articles for article (PubMed ID: 14613264)
1. Prognostic factors in a large cohort of patients with early undifferentiated inflammatory arthritis after application of a structured management protocol.
Quinn MA; Green MJ; Marzo-Ortega H; Proudman S; Karim Z; Wakefield RJ; Conaghan PG; Emery P
Arthritis Rheum; 2003 Nov; 48(11):3039-45. PubMed ID: 14613264
[TBL] [Abstract][Full Text] [Related]
2. How aggressive should initial therapy for rheumatoid arthritis be? Factors associated with response to 'non-aggressive' DMARD treatment and perspective from a 2-yr open label trial.
Matteson EL; Weyand CM; Fulbright JW; Christianson TJ; McClelland RL; Goronzy JJ
Rheumatology (Oxford); 2004 May; 43(5):619-25. PubMed ID: 14983105
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of early intervention with intraarticular corticosteroids followed by sulfasalazine versus conservative treatment in early oligoarthritis.
Marzo-Ortega H; Green MJ; Keenan AM; Wakefield RJ; Proudman S; Emery P
Arthritis Rheum; 2007 Feb; 57(1):154-60. PubMed ID: 17266089
[TBL] [Abstract][Full Text] [Related]
4. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
Proudman SM; Keen HI; Stamp LK; Lee AT; Goldblatt F; Ayres OC; Rischmueller M; James MJ; Hill CL; Caughey GE; Cleland LG
Semin Arthritis Rheum; 2007 Oct; 37(2):99-111. PubMed ID: 17391739
[TBL] [Abstract][Full Text] [Related]
5. Contemporary use of disease-modifying drugs in the management of patients with early rheumatoid arthritis in Norway.
Nikolaisen C; Kvien TK; Mikkelsen K; Kaufmann C; Rødevand E; Nossent JC
Scand J Rheumatol; 2009; 38(4):240-5. PubMed ID: 19229766
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts.
van der Woude D; Young A; Jayakumar K; Mertens BJ; Toes RE; van der Heijde D; Huizinga TW; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2262-71. PubMed ID: 19644846
[TBL] [Abstract][Full Text] [Related]
7. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies.
Saunders SA; Capell HA; Stirling A; Vallance R; Kincaid W; McMahon AD; Porter DR
Arthritis Rheum; 2008 May; 58(5):1310-7. PubMed ID: 18438851
[TBL] [Abstract][Full Text] [Related]
8. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
9. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.
Rantalaiho V; Korpela M; Hannonen P; Kautiainen H; Järvenpää S; Leirisalo-Repo M; Hakala M; Puolakka K; Julkunen H; Luosujärvi R; Möttönen T;
Arthritis Rheum; 2009 May; 60(5):1222-31. PubMed ID: 19404945
[TBL] [Abstract][Full Text] [Related]
10. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis.
James HM; Gillis D; Hissaria P; Lester S; Somogyi AA; Cleland LG; Proudman SM
J Rheumatol; 2008 Apr; 35(4):562-71. PubMed ID: 18322994
[TBL] [Abstract][Full Text] [Related]
11. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up.
Verstappen SM; van Albada-Kuipers GA; Bijlsma JW; Blaauw AA; Schenk Y; Haanen HC; Jacobs JW;
Ann Rheum Dis; 2005 Jan; 64(1):38-43. PubMed ID: 15130899
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of triple DMARD therapy in patients with RA with suboptimal response to methotrexate.
O'Dell JR; Haire C; Erikson N; Drymalski W; Palmer W; Maloley P; Klassen LW; Wees S; Moore GF
J Rheumatol Suppl; 1996 Mar; 44():72-4. PubMed ID: 8833058
[TBL] [Abstract][Full Text] [Related]
13. Predictors of outcome in patients with oligoarthritis: results of a protocol of intraarticular corticosteroids to all clinically active joints.
Green M; Marzo-Ortega H; Wakefield RJ; Astin P; Proudman S; Conaghan PG; Hordon L; Emery P
Arthritis Rheum; 2001 May; 44(5):1177-83. PubMed ID: 11352252
[TBL] [Abstract][Full Text] [Related]
14. Choice of second-line disease-modifying antirheumatic drugs after failure of methotrexate therapy for rheumatoid arthritis: a decision tree for clinical practice based on rheumatologists' preferences.
Fautrel B; Guillemin F; Meyer O; de Bandt M; Berthelot JM; Flipo RM; Lioté F; Maillefert JF; Wendling D; Saraux A; Combe B; Le Loët X; ; ;
Arthritis Rheum; 2009 Apr; 61(4):425-34. PubMed ID: 19333993
[TBL] [Abstract][Full Text] [Related]
15. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry.
Weaver AL; Lautzenheiser RL; Schiff MH; Gibofsky A; Perruquet JL; Luetkemeyer J; Paulus HE; Xia HA; Leff JA;
Curr Med Res Opin; 2006 Jan; 22(1):185-98. PubMed ID: 16393444
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis.
Nikolaisen C; Rekvig OP; Nossent HC
Scand J Rheumatol; 2005; 34(4):269-76. PubMed ID: 16195159
[TBL] [Abstract][Full Text] [Related]
18. Early suppression of disease activity is essential for maintenance of work capacity in patients with recent-onset rheumatoid arthritis: five-year experience from the FIN-RACo trial.
Puolakka K; Kautiainen H; Möttönen T; Hannonen P; Korpela M; Hakala M; Järvinen P; Ahonen J; Forsberg S; Leirisalo-Repo M;
Arthritis Rheum; 2005 Jan; 52(1):36-41. PubMed ID: 15641055
[TBL] [Abstract][Full Text] [Related]
19. Autoantibodies in early seropositive rheumatoid arthritis, before and during disease modifying antirheumatic drug treatment.
Paulus HE; Wiesner J; Bulpitt KJ; Patnaik M; Law J; Park GS; Wong WK
J Rheumatol; 2002 Dec; 29(12):2513-20. PubMed ID: 12465144
[TBL] [Abstract][Full Text] [Related]
20. Persistence of mild, early inflammatory arthritis: the importance of disease duration, rheumatoid factor, and the shared epitope.
Green M; Marzo-Ortega H; McGonagle D; Wakefield R; Proudman S; Conaghan P; Gooi J; Emery P
Arthritis Rheum; 1999 Oct; 42(10):2184-8. PubMed ID: 10524691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
